McKesson Corporation (MCK)
NYSE:MCK
Want to see MCK full AI Analyst Report?
MCK Stock Chart & Stats
$760.57
$1.72(0.29%)
At close: 4:00 PM EST
$760.57
$1.72(0.29%)
Day’s Range― - ―
52-Week Range$637.00 - $999.00
Previous CloseN/A
Volume137.88K
Average Volume (3M)1.24M
Market Cap
$91.96B
Enterprise Value$98.37B
Total Cash (Recent Filing)$3.98B
Total Debt (Recent Filing)$8.61B
Price to Earnings (P/E)20.0
Beta0.19
Next Earnings
Aug 05, 2026EPS Estimate
9.68Next Dividend Ex-DateN/A
Dividend Yield0.37%
Share Statistics
EPS (TTM)38.64
Shares Outstanding117,077,740
10 Day Avg. Volume790,554
30 Day Avg. Volume1,237,097
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)-49.24
Price to Sales (P/S)0.27
P/FCF Ratio18.70
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue0.24
Enterprise Value/Gross Profit6.76
Enterprise Value/Ebitda14.02
Forecast
1Y Price Target
$935.55Price Target Upside23.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)44.26
Revenue Forecast (FY)$432.87B
Bulls Say, Bears Say
Bulls Say
Scale & Revenue RecoveryMcKesson's massive scale and clear revenue recovery provide durable competitive advantage: a broad distribution network and large customer contracts drive stable volumes, bargaining power with manufacturers, and the operating base to fund capex, separation execution, and strategic investments over multiple years.
Specialty & Oncology MomentumRapid oncology and multispecialty expansion shifts mix toward higher-value services. Provider additions, targeted acquisitions and service scale create recurring, stickier revenue streams with better margin upside than commodity distribution, supporting sustained segment-level profitability and strategic differentiation.
Strong Cash Generation And LiquidityConsistent, multi-billion dollar operating cash flow underpins capital returns and reinvestment capacity. Strong cash conversion supports buybacks, funding of the Medical‑Surgical separation and modernization programs while credit facilities enhance liquidity, giving durable financial flexibility across business cycles.
Bears Say
Structurally Thin MarginsDistribution economics leave McKesson exposed to small absolute margin moves; mix shifts, manufacturer pricing and reimbursement changes (eg IRA effects) can materially swing profitability. Low margin structure reduces ability to absorb cost inflation or unexpected operating setbacks over the medium term.
Leverage And Prior Negative EquityA history of negative equity and meaningful reliance on debt increases financial rigidity and stakeholder sensitivity to shocks. Ongoing separation financing and covenanted credit facilities constrain flexibility, raising refinancing and covenant breach risk if cash flow softens over the next several quarters.
FCF Volatility And Separation-related CostsPlanned step-down in free cash flow combined with higher interest from separation financing reduces the cash buffer for buybacks, M&A or working-capital swings. FCF volatility driven by working capital and category timing increases execution risk around separation and capital allocation over the medium term.
McKesson News
MCK FAQ
What was McKesson Corporation’s price range in the past 12 months?
McKesson Corporation lowest stock price was $637.00 and its highest was $999.00 in the past 12 months.
What is McKesson Corporation’s market cap?
McKesson Corporation’s market cap is $91.96B.
When is McKesson Corporation’s upcoming earnings report date?
McKesson Corporation’s upcoming earnings report date is Aug 05, 2026 which is in 48 days.
How were McKesson Corporation’s earnings last quarter?
McKesson Corporation released its earnings results on May 07, 2026. The company reported $11.69 earnings per share for the quarter, beating the consensus estimate of $11.565 by $0.125.
Is McKesson Corporation overvalued?
According to Wall Street analysts McKesson Corporation’s price is currently Undervalued.
Does McKesson Corporation pay dividends?
McKesson Corporation pays a Quarterly dividend of $0.82 which represents an annual dividend yield of 0.37%. See more information on McKesson Corporation dividends here
What is McKesson Corporation’s EPS estimate?
McKesson Corporation’s EPS estimate is 9.68.
How many shares outstanding does McKesson Corporation have?
McKesson Corporation has 117,077,740 shares outstanding.
What happened to McKesson Corporation’s price movement after its last earnings report?
McKesson Corporation reported an EPS of $11.69 in its last earnings report, beating expectations of $11.565. Following the earnings report the stock price went down -2.474%.
Which hedge fund is a major shareholder of McKesson Corporation?
Currently, no hedge funds are holding shares in MCK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
McKesson Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$935.55 (23.01% Upside)
$935.55 (23.01% Upside)
Blogger Sentiment
Bullish
MCK Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 323.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 2.2%
Last 30 Days ▲ 2.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
8.08%
12-Months-Change
Fundamentals
Return on Equity
-265.44%
Trailing 12-Months
Asset Growth
9.56%
Trailing 12-Months
Company Description
McKesson Corporation
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.
MCK Company Deck
MCK Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
McKesson reported a strong fiscal 2026 with double-digit revenue, operating profit and EPS growth, robust cash generation and material progress on strategic initiatives (oncology expansion, biopharma scale, supply chain modernization, and Medical‑Surgical separation). The company is returning significant capital to shareholders and reaffirmed long‑term targets. Offsetting risks include branded pricing pressure (IRA effects), sequential GLP‑1 volatility, ongoing integration and corporate expense investments, and near‑term cash flow/interest impacts related to separation financing. On balance the positives (broad-based growth, margin expansion, cash returns, strategic progress) outweigh the negatives, though the business faces near-term variability and execution/approval risks tied to the Medical‑Surgical separation.View all MCK earnings summariesMCK Revenue Breakdown
83.45% North American Pharmaceutical
12.00% Oncology & Multispecialty
1.44% Prescription Technology Solutions
2.85% Medical-Surgical Solutions
0.26% Other
MCK Stock 12 Month Forecast
Average Price Target
$935.55
▲(23.01% Upside)
Technical Analysis
Ownership Overview
0.06% Insiders
23.57% Mutual Funds
14.85% Other Institutional Investors
38.62% Public Companies and Individual Investors